- Eli Lilly's experimental drug solanezumab failed to prevent memory loss in a study of healthy older people with a high risk of developing Alzheimer's disease.
- The drug was no better than a placebo at slowing decline over about 4.5 years of treatment.
- Solanezumab targets dissolvable forms of amyloid that float in the blood and brain.
- Newer drugs remove amyloid plaques and have slowed cognitive decline in early-stage Alzheimer's patients.
- About 36% of patients in the study developed clinical symptoms of Alzheimer's disease, with a similar rate of progression in the treatment and placebo groups.
Eli Lilly Drug Fails to Prevent Alzheimer’s in Study
The drug was no better than placebo at averting the condition
Joseph Walker
/cloudfront-us-east-2.images.arcpublishing.com/reuters/BIWQBPADDROF5LP7NMSSMUCRLY.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
